NFKB1 and acute myeloid leukemia: It should, therefore, be emphasized that the alterations in GEP described in this study might not be specific for NF-κB inhibition in AML cells, but should possibly be regarded as a model for the potential biological effects of NF-κB inhibition in cancer patients.